Efficacy outcomes after ≥18 months’ follow-up
| Event . | Arm T (n = 33) . | Arm T/L (n = 33) . | Arm T/L IPI 3–5 (n = 22) . |
|---|---|---|---|
| ORR, n (%) (95% CI) | |||
| CR or PR (at EoT) | 25 (75.8) (57.7-88.9) | 27 (81.8) (64.5-93.0) | 18 (81.8) (59.7-94.8) |
| CR or PR (best response across all visits) | 30 (90.9) (75.7-98.1) | 31 (93.9) (79.8-99.3) | 20 (90.9) (70.8-98.9) |
| 18-mo DoR rate, % (95% CI) | 72.7 (52.7-85.3) | 78.7 (58.5-89.9) | 76.6 (48.8-90.5) |
| 18-mo DoCR rate, % (95% CI) | 74.5 (53.8-87.0) | 86.5 (63.8-95.5) | 80.0 (50.0-93.1) |
| 24-mo PFS rate, % (95% CI) | 72.7 (52.7-85.3) | 76.8 (57.1-88.3) | 73.6 (47.3-88.2) |
| 24-mo OS rate, % (95% CI) | 90.3 (72.9-96.8) | 93.8 (77.3-98.4) | 95.2 (70.7-99.3) |
| Event . | Arm T (n = 33) . | Arm T/L (n = 33) . | Arm T/L IPI 3–5 (n = 22) . |
|---|---|---|---|
| ORR, n (%) (95% CI) | |||
| CR or PR (at EoT) | 25 (75.8) (57.7-88.9) | 27 (81.8) (64.5-93.0) | 18 (81.8) (59.7-94.8) |
| CR or PR (best response across all visits) | 30 (90.9) (75.7-98.1) | 31 (93.9) (79.8-99.3) | 20 (90.9) (70.8-98.9) |
| 18-mo DoR rate, % (95% CI) | 72.7 (52.7-85.3) | 78.7 (58.5-89.9) | 76.6 (48.8-90.5) |
| 18-mo DoCR rate, % (95% CI) | 74.5 (53.8-87.0) | 86.5 (63.8-95.5) | 80.0 (50.0-93.1) |
| 24-mo PFS rate, % (95% CI) | 72.7 (52.7-85.3) | 76.8 (57.1-88.3) | 73.6 (47.3-88.2) |
| 24-mo OS rate, % (95% CI) | 90.3 (72.9-96.8) | 93.8 (77.3-98.4) | 95.2 (70.7-99.3) |